Date:9/3/2008

fect of start-up costs of new programs and facilities, including our recent and planned expansions; the adequacy of restructuring and similar charges as compared to actual expenses; the degree of success and the costs of efforts to improve the financial performance of our Mexican operations and the outcome of our review of our other North American footprint; possible unexpected costs and operating disruption in transitioning programs; the costs and inherent uncertainties of pending litigation; market reaction to the recently completed share repurchase program; the effect of general economic conditions and world events (such as increases in oil prices, terrorism and war in the Middle East); the impact of increased competition; and other risks detailed in the Company's Securities and Exchange Commission filings (particularly in Part II, Item 1A of our quarterly report on Form 10-Q for the quarter ended June 28, 2008).

'/>"/>

SOURCE Plexus Corp. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related biology technology :

1. Plexus Q2 Earnings Release on April 23rd After Market Close and Conference Call on April 24th at 8:30 am E.T.
2. Plexus Q2 Earnings Release on April 23rd After Market Close and Conference Call on April 24th at 8:30 am E.T.
3. Anesiva Announces Conference Call and Webcast to Discuss Updates to Corporate Strategy and Milestones
4. Anesiva Announces Appointment of William Houghton, M.D. as Senior Vice President and Chief Medical Officer
5. Atrial Fibrillation Month - StopAfib.org Announces September Focus on Life-Threatening Irregular Heartbeat
6. Oncothyreon announces prioritization plan for development programs
7. /R E P E A T -- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours/
8. Purdue Pharma L.P. Announces Resolution of OxyContin(R) Patent Lawsuit with Mallinckrodt Inc.
9. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
10. Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
11. Dendreon Announces Webcast Presentation at Newsmakers in the Biotech Industry Conference